Prostate Cancer P D:前列腺癌重点治疗疗法风险-回报平衡研究

2019-02-02 AlexYang MedSci原创

局部前列腺癌的重点治疗疗法(FT)为那些需求积极治疗男性患者的一种治疗选择。尽管相对新的、已经存在的研究已经表明大多数经历FT的男性倾向于维持与治疗前同样的泌尿-生殖功能水平,然而,作为治疗策略决定过程中的一部分,虽然许多前列腺在FT后仍旧保持完整,这些男性患者仍旧需要平衡耐受性与更大的复发风险。最近,有研究人员为了探索上述得失,他们使用了决策模型。研究发现,与根治性前列腺切除(RP)相关的功能并

局部前列腺癌的重点治疗疗法(FT)为那些需求积极治疗男性患者的一种治疗选择。尽管相对新的、已经存在的研究已经表明大多数经历FT的男性倾向于维持与治疗前同样的泌尿-生殖功能水平,然而,作为治疗策略决定过程中的一部分,虽然许多前列腺在FT后仍旧保持完整,这些男性患者仍旧需要平衡耐受性与更大的复发风险。

最近,有研究人员为了探索上述得失,他们使用了决策模型。研究发现,与根治性前列腺切除(RP)相关的功能并发症的负担明显,由于治疗诱导的尿失禁与勃起功能障碍,每位患者平均损失243天健康时间。另外考虑到目前医疗护理的有效性差距,研究人员探讨了疾病进展的最坏结果的死亡率可能会增加多少,从而仍然产生净健康效益。为了达到上述目的,研究人员将FT与RP比较,绘制了净健康效益/FT损失比例,从而来表示不同水平的功能保留和死亡率的增加。

最后,研究人员指出,他们相信他们的建模实践能够帮助未来的研究来加强关于男性患者怎样选择治疗方法的理解。

原始出处:

Anouck Kluytmans, Jurgen J. Fütterer, Mark Emberton et al. Exploring the risk-reward balance in focal therapy for prostate cancer-a contribution to the debate. Prostate Cancer P D. 21 January 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=359944, encodeId=1f5435994492, content=前列腺癌男性死亡率高, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Feb 04 14:15:52 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364448, encodeId=f67f1364448f7, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Feb 04 07:09:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602113, encodeId=dad21602113e7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Feb 04 07:09:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791566, encodeId=ce851e915660a, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 13 17:09:00 CST 2019, time=2019-02-13, status=1, ipAttribution=)]
    2019-02-04 flysky120

    前列腺癌男性死亡率高

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=359944, encodeId=1f5435994492, content=前列腺癌男性死亡率高, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Feb 04 14:15:52 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364448, encodeId=f67f1364448f7, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Feb 04 07:09:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602113, encodeId=dad21602113e7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Feb 04 07:09:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791566, encodeId=ce851e915660a, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 13 17:09:00 CST 2019, time=2019-02-13, status=1, ipAttribution=)]
    2019-02-04 lsndxfj
  3. [GetPortalCommentsPageByObjectIdResponse(id=359944, encodeId=1f5435994492, content=前列腺癌男性死亡率高, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Feb 04 14:15:52 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364448, encodeId=f67f1364448f7, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Feb 04 07:09:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602113, encodeId=dad21602113e7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Feb 04 07:09:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791566, encodeId=ce851e915660a, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 13 17:09:00 CST 2019, time=2019-02-13, status=1, ipAttribution=)]
    2019-02-04 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=359944, encodeId=1f5435994492, content=前列腺癌男性死亡率高, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Feb 04 14:15:52 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364448, encodeId=f67f1364448f7, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Feb 04 07:09:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602113, encodeId=dad21602113e7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Feb 04 07:09:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791566, encodeId=ce851e915660a, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 13 17:09:00 CST 2019, time=2019-02-13, status=1, ipAttribution=)]

相关资讯

NEJM:前列腺癌:根治性前列腺切除术vs观望等待

2018年12月,瑞典、英国、芬兰等国学者在《N Engl J Med》发表了前列腺癌患者根治性前列腺切除术或观望等待:29年随访。

Int J Impot Res:根治性前列腺切除术前列腺癌患者中的术前术后睾酮水平研究

根治性前列腺切除是局部前列腺癌的一种治疗选择。已经报道的数据表明根治性前列腺切除与睾酮水平的增加和减少有关。最近,有研究人员阐释了根治性前列腺切除术前后的血清睾酮水平,以及血清睾酮水平与前列腺情况的相关性。研究包括了85名患有局部和局部晚期前列腺癌且选择根治性前列腺切除术,而之前没有进行雄激素阻断治疗的患者,并搜集了他们的人口统计资料、术前和术后的睾酮水平、性激素结合球蛋白、白蛋白、前列腺特异性抗

Prostate Cancer P D:新系统性治疗对转移去势难治性前列腺癌患者总生存影响研究

2004年,多烯紫杉醇展现出了能够延长转移去势难治性前列腺癌(mCRPC)患者总生存(OS)的效果。自从2010年,已经出现了5中系统性的治疗且能够延长mCRPC患者的OS。最近,有研究人员评估了这些新疗法对mCRPC患者的OS的整体影响。研究包括了2个群体,分别是2004年到2007年间有限药物治疗的群体A和2010年到2013年接受新疗法的群体B。研究发现,与群体A(n=318)比较,接受新疗

盘点2018:前列腺癌治疗新进展

目前已有不少文献显示转移性前列腺癌、高度恶性前列腺癌、致死性前列腺癌往往伴有BRCA2、BRCA1、ATM等DNA修复基因的胚系突变。在新型内分泌治疗药物已占有重要地位的今天,这些胚系突变是否可以预测其疗效还存在争议。

欧盟委员会批准前列腺癌新药Erleada(apalutamide):口服雄激素受体抑制剂

Erleada(apalutamide)已被批准用于治疗转移性疾病高风险的非转移性去势抵抗性前列腺癌(nmCRPC)患者。

Nat Commun:ONECUT2是神经内分泌前列腺癌的驱使因子

神经内分泌前列腺癌(NEPC)是一种致死性的疾病,可以通过雄激素受体(AR)信号在神经内分泌分化过程中的缺失来鉴定。临床上、基因组水平上和表观遗传水平上来讲,NEPC类似于其他类型的低分化程度的神经内分泌肿瘤(NETs)。最近,有研究人员通过pan-NET分析,鉴定了ONECUT2可以作为低分化NETs的候选主要转录调控因子。ONECUT2在前列腺恶性肿瘤中的异位表达能够与缺氧协同来抑制雄激素信号